RAGE gene three polymorphisms with Crohn's disease susceptibility in Chinese Han population

Zheng-Ting Wang, Jia-Jia Hu, Rong Fan, Jie Zhou, Jie Zhong

Objective: To investigate the association of three polymorphisms in the receptor for advanced glycation end products (RAGE) gene with Crohn's disease (CD) risk in a Chinese population.

Methods: A hospital-based case-control association study involving 312 CD patients and 479 healthy controls was conducted. Peripheral blood samples were collected from 791 study subjects, and genomic DNA was extracted. Genotyping was performed using polymerase chain reaction-ligase detection reaction method. The association between polymorphic genotype and CD predisposition was determined using odds ratio and 95% confidence interval (CI). Data were analyzed using Haplo.stats program.

Results: Significant differences were observed between patients and controls in allele/genotype distributions of rs2070600 (P = 0.02). The risk for CD associated with the rs1800624-A mutant allele decreased by 36% (95%CI: 0.47-0.88, P = 0.005) under the additive model and by 35% (95%CI: 0.46-0.91, P = 0.013) under the dominant model. Carriers of rs2070600-A mutant allele showed a 37% (95%CI: 1.02-1.83, P = 0.036) increased risk of developing CD relative to the GG genotype carriers. In haplotype analysis, haplotype T-A-G (in the order rs1800625, rs1800624, and rs2070600) decreased the odds of CD by 33% (95%CI: 0.49-0.94, P = 0.018).

Conclusion: CD is an immune-related disease with genetic predisposition. Genetic defects in the RAGE gene are strongly associated with CD in Chinese population.

Keywords: Receptor for advanced glycation end products; Polymorphism; Crohn's diseases; Susceptibility; Association study

Core tip: The receptor for advanced glycation end products (RAGE) is a pattern recognition receptor involved in several pathophysiological processes associated with inflammation. Therefore, we considered that RAGE gene is a candidate gene susceptible to Crohn's disease (CD). This study is the first to investigate the association of the three most commonly studied polymorphisms in RAGE gene with CD risk in a Chinese population. The results suggest that RAGE rs1800624 and rs2070600 polymorphisms are associated with CD occurrence. The present findings support the hypothesis that a genetically impaired innate defense immunity system is a predisposing factor in the etiology of CD.
INTRODUCTION

Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory condition of the gastrointestinal tract that comprises two main subtypes, namely, Crohn's disease (CD) and ulcerative colitis (UC), which have overlapping but distinct clinical and pathological features. Considerable efforts have been devoted to elucidating the etiology and pathogenesis of IBD, but underlying regulatory and molecular mechanisms remain elusive. Epidemiological studies have documented that first-degree relatives of individuals with IBD have approximately 20-fold to 50-fold increased risk of developing the disease compared with the general population for CD and 10-fold to 20-fold increased risk for developing UC[3,4], suggesting a genetic basis for inheritance of IBD. Genome-wide linkage analyses have identified multiple candidate regions on several chromosomes for IBD. Meanwhile, numerous immunity-related genes have been found to be associated with IBD susceptibility regions[5-8]. As a result of the importance of immunity in IBD, investigations on IBD-susceptibility genes involved in immunity have increasingly elicited research interest.

The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin protein family of cell surface molecules[9], and was initially isolated as the receptor of advanced glycation end products (AGEs) that accumulate during diabetes and senescence as a result of nonenzymatic glycation and oxidation of proteins and lipids[7]. RAGE has since been shown to bind a diverse set of ligands in addition to AGEs, including high-mobility group box-1, several members of the S100 protein family and β amyloid peptides, leading to the activation of several proinflammatory signaling pathways[10,11]. Presently, RAGE is a pattern recognition receptor involved in several pathophysiological processes associated with inflammation, such as diabetes complications[12], arthritis[13], systemic lupus erythematosus[14], multiple sclerosis[15], as well as CD[16]. In addition, animal model studies suggest that RAGE has an important function in innate defense mechanisms[17]. Meanwhile, recent studies have discovered nearly 20 naturally occurring RAGE-splicing variants in humans[18]. These isoforms are characterized by whole or parts of mRNA transcripts with missing or additional exons/introns or resulting from alternative splicing of the RAGE pre-mRNA and gene expression regulation[19]. Subsequent studies have presented convincing statistical evidence for a novel functional single nucleotide polymorphism, -374T/A, in RAGE being the CD susceptible locus in a German population, but not in an American population[13].

Considering that susceptibility genes in CD vary across different ethnic groups, we performed a hospital-based case-control association study on the three widely evaluated polymorphisms of RAGE gene and assessed the association between RAGE haplotypes and CD.

MATERIALS AND METHODS

Study populations

A hospital-based case-control study was conducted, involving 312 sporadic patients with CD and 479 healthy volunteers. All patients were recruited through the Outpatient Clinic at the Department of Gastroenterology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine as part of an ongoing project to examine genetic factors that contribute to the etiology of IBD. The demographics in the study population are summarized in Table 1. In this study, 42 patients were diagnosed under 17 years old in the CD group and there were 63 patients in the control group, without statistical difference in the proportion ($P = 0.97$).

Cases and controls were well matched by age and gender. Informed consent was obtained from all participants, and the study was approved by the Institutional Ethics Board of the Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.

Genotyping

Blood samples (1 mL) were collected, and genomic DNA was extracted from white blood cells using TIANamp Blood DNA Kit (Tiangen Biotech Co., Ltd., Beijing, China). Genotyping was conducted by the PCR-ligase detection reactions (LDR) method using ABI 9600 system (Applied Biosystems, United States)[20]. The following cy-

| Characteristics | CD patients | Control subjects |
|-----------------|-------------|------------------|
| Number          | 312         | 479              |
| Male/female     | 205/107     | 308/171          |
| Age, mean ± SD (yr) | 34.0 ± 13.0 | 36.5 ± 15.1 |
| Age at diagnosis (ys) |           |                  |
| < 17            | 42          | 63               |
| 17-40           | 212         | 324              |
| > 40            | 58          | 92               |
| CD behavior     |             |                  |
| Inflammatory    | 179         |                  |
| Strictureing    | 90          |                  |
| Penetrating     | 43          |                  |
| CD location     |             |                  |
| Ileum           | 194         |                  |
| Colon           | 27          |                  |
| Cecum           | 91          |                  |
| Perianal lesions|             |                  |
| Yes             | 92          |                  |
| No              | 220         |                  |
| Appendectomy    |             |                  |
| Yes             | 18          |                  |
| No              | 294         |                  |
| Abdominal operation |         |                  |
| Yes             | 72          |                  |
| No              | 240         |                  |

CD: Crohn’s disease.
Single-locus analysis

No deviations from Hardy-Weinberg equilibrium were found for all studied polymorphisms in the controls ($P > 0.05$). The genotype/allele distributions of the three selected polymorphisms in RAGE are shown in Table 2. Significant differences between CD patients and controls were observed in allele and genotype distributions of rs1800624 ($P_{\text{allele}} = 0.012$ and $P_{\text{genotype}} = 0.005$) and in allele distributions of rs2070600 ($P = 0.022$).

Notably, for rs1800624, the risk associated with mutant allele or genotype decreased by 36% (95%CI: 0.47-0.88) under the additive model and by 35% (95%CI: 0.46-0.91) under the dominant model. For rs2070600, a significant difference in association with CD under the additive (OR = 1.29; 95%CI: 1.03-1.62) and dominant (OR = 1.37; 95%CI: 1.02-1.83) models was observed. No significant association was detected for rs1800625 under the three genetic models.

Haplotype analysis

Haplotype frequencies of the three polymorphisms examined were estimated and compared between cases and controls (Table 3). The frequency of haplotype T-A-G (in the order rs1800625, rs1800624, and rs2070600) was significantly lower ($P = 0.005$) in patients, whereas the frequency of haplotype T-T-A was significantly higher ($P = 0.027$) in patients compared with the controls. After assigning the most common haplotype T-T-G as the reference, haplotype T-A-G decreased the odds of CD by 33% (95%CI: 0.49-0.94, $P = 0.018$).

Power calculation

Power calculation was performed to estimate the risk of obtaining false-negative results because of small sample size. Based on the two-sided test at the 0.05 significance level, this study exhibited 69% and 53% power in successfully detecting a significant association between rs1800624 and rs2070600 polymorphisms and risk of

---

Table 2  Genotype distributions and allele frequencies of the studied polymorphisms in patients and controls, and their risk prediction for Crohn’s disease under three genetic models of inheritance

| Polymorphism  | Patients ($n = 312$) | Controls ($n = 479$) | $P$ ($\chi^2$) | Genetic models | OR; 95%CI |
|--------------|----------------------|----------------------|----------------|----------------|-----------|
| rs1800624    |                       |                      |                |                |           |
| TT           | 248                  | 343                  | 0.012          | Additive       | 0.64; 0.47-0.88 |
| AT           | 62                   | 123                  |                | Dominant       | 0.65; 0.46-0.91 |
| AA           | 2                    | 13                   |                | Recessive      | 0.23; 0.05-1.03 |
| A            | 10.6%                | 15.6%                | 0.005          |               |           |
| rs1800625    |                       |                      |                |                |           |
| TT           | 228                  | 333                  | 0.460          | Additive       | 0.98; 0.73-1.33 |
| CT           | 82                   | 118                  |                | Dominant       | 1.03; 0.75-1.42 |
| CC           | 2                    | 8                    |                | Recessive      | 0.38; 0.08-1.80 |
| C            | 13.8%                | 14.0%                | 0.940          |               |           |
| rs2070600    |                       |                      |                |                |           |
| GG           | 174                  | 303                  | 0.086          | Additive       | 1.29; 1.03-1.62 |
| AG           | 112                  | 148                  |                | Dominant       | 1.37; 1.02-1.83 |
| AA           | 26                   | 28                   |                | Recessive      | 1.46; 0.84-2.55 |
| A            | 26.3%                | 21.3%                | 0.022          |               |           |

OR: Odds ratio.

---

Statistical analysis

Comparisons between CD patients and controls were conducted using unpaired $t$ test for continuous variables and $\chi^2$ test for categorical variables. To avoid gross genotyping error, all polymorphisms were checked for consistency with Hardy-Weinberg equilibrium on a contingency table of observed-versus-predicted genotype frequencies using Pearson $\chi^2$ test or Fisher’s exact test. Genotypes were compared by logistic regression analysis under assumptions of additive, dominant, and recessive models of inheritance. $P < 0.05$ was considered statistically significant. Haplotype frequencies were estimated using the haplo.em program, and odds ratio (ORs) and 95% confidence interval (CI) were estimated using haplo.stats and haplo.glm programs according to a generalized linear model [29]. The haplo.score was used to model an individual’s phenotype as a function of each inferred haplotype, which was weighted by their estimated probability to account for haplotype ambiguity. The haplo.em, haplo.glm, and haplo.score were evaluated using haplo.stats software (version 1.4.0) developed using R (http://www.r-project.org/). Study power was estimated using PS Power and Sample Size Calculations software (version 3.0).
CD under a dominant genetic model, respectively.

**DISCUSSION**

In this study, we investigated the role of three potential polymorphisms of RAGE gene in the risk of CD susceptibility in a Han Chinese population. The results reveal that the RAGE gene polymorphisms and the haplotype were associated with CD. Although the haplotype T-A-G (rs1800625-rs1800624-rs2070600), had low penetrance, it was negatively correlated with CD and could have a protective function in the latter. To the authors’ knowledge, the present study is the first to explore the genetic susceptibility of RAGE gene to CD in Chinese population.

The rs1800624 polymorphism located at position -374 of the promoter region could be a functional polymorphism that results in reduced binding of a nuclear factor to a regulatory element of the RAGE gene promoter. In vitro experiments by Hudson et al. demonstrated that -374A resulted in a threefold increase in transcriptional activity compared with the T allele. Däbritz et al. found that -374T/A RAGE polymorphism is negatively associated with CD in a German population, supporting the hypothesis that the -374T/A RAGE polymorphism increases the levels of circulating soluble RAGE to neutralize proinflammatory mediators. However, this claim warrants further investigation.

Another variant (rs2070600, also known as G82S polymorphism) that causes a glycine-to-serine substitution at position 82 within the V-domain exhibits significantly different distribution between CD and control individuals (P allele = 0.022). The rs2070600 polymorphism is located in an exon in a region that has a crucial function in ligand binding. The 82S variant increases the ligand-binding affinity of the receptor, and consequently increases nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation and inflammatory gene expression. In addition, the G82S polymorphism is associated with reduced levels of soluble RAGE that magnifies the contribution from RAGE toward inflammation in a number of diseases. The G82S RAGE polymorphism is associated with arthritis. However, Däbritz et al. did not detect any association between G82S polymorphism and CD in either German or American population. They found that the minor A allele frequency of this polymorphism was below 5% in all study samples. In contrast, in the present study, the minor A allele frequencies were 26.3% and 21.3% in the cases and in the controls, respectively. The discrepancy in the results may be mainly explained by the heterogeneous genetic predispositions of individuals of different ethnicities. Genetic markers representing predisposition to IBD vary across geographical and racial groups. As proven by our previous meta-analyses, CD14 gene C-260T polymorphism exhibited remarkable heterogeneity with UC across ethnic groups, with statistical significance in Asians but not in Caucasians. However, considering the relatively smaller sample size in the present study, more studies are required to validate the effects for RAGE G82S.

In this study, haplotype analysis of the rs1800625-rs1800624-rs2070600 combination revealed four main and rare haplotypes. The common haplotype T-T-G showed a similar frequency between CD and control individuals (49.4% vs 49.1%). Compared with the common haplotype, haplotype T-A-G showed a highly significant negative correlation between CD and control individuals (10.6% vs 15.6%, P = 0.0049; OR = 0.67), suggesting that it is a protective haplotype. Haplotype analysis further confirmed the results that rs1800624 and rs2070600 are the susceptible loci for CD in the Chinese population.

However, this study has several drawbacks. First, the sample size is relatively small and may not produce efficient statistical power to detect a small genetic effect, resulting in a fluctuated estimation. Second, limited polymorphisms of RAGE gene associated with susceptibility to CD were shown, and other unidentified polymorphisms that influence the development of CD still remain to be discovered. Therefore, further related studies of a large sample size from different ethnic origins and biological studies should be carried out to verify this association. Third, data on circulating soluble RAGE levels are unavailable, so RAGE levels cannot be compared across genotypes.

In conclusion, this study revealed that polymorphisms and haplotypes of the RAGE gene are significantly associated with susceptibility to CD in the Chinese population. Moreover, this study leaves open the question of divergent genetic profiles across different ethnic groups. This study provides supporting evidence for further investigation on pathophysiological mechanisms of RAGE genes in CD.

### COMMENTS

**Background**
The incidence of Crohn’s disease (CD) is rising in China, although the exact etiology of CD remains elusive. Genome-wide linkage analyses and association

---

**Table 3** Haplotype frequencies of the studied polymorphisms in patients and controls, and their risk prediction for Crohn’s disease

| haplotype | Case     | Control  | Hapscore | P value | Psim OR 95%CI | P value |
|-----------|----------|----------|----------|---------|----------------|---------|
| T-T-G     | 49.40%   | 49.10%   | 0.075    | 0.94    | 0.92 Reference | 0.0049 |
| T-T-A     | 26.30%   | 21.30%   | 2.21     | 0.027   | 0.032 | 1.2 | 0.94-1.53 | 0.14 |
| T-A-G     | 10.60%   | 15.60%   | -2.82    | 0.005   | 0.002 | 0.67 | 0.49-0.94 | 0.018 |
| C-T-G     | 13.80%   | 14.00%   | -0.12    | 0.91    | 0.88 | 0.97 | 0.70-1.33 | 0.83 |

Alleles in haplotype were presented in order of polymorphisms rs1800625, rs1800624 and rs2070600. OR: Odds ratio; Psim: Simulated P.
This research is a well-designed case-control study demonstrating that RAGE rs1800624 and CD susceptibility risk are limited. This study is the first to investigate the association between the three most commonly studied polymorphisms in RAGE gene and CD risk in a Chinese population. This study adds evidence for a genetically impaired innate defense immunity system as one predisposing factor in the etiology of CD.

**REFERENCES**

1. Zheng CQ, Hu CZ, Zeng ZS, Lin LJ, Gu GG. Progress in searching for susceptibility gene for inflammatory bowel disease by positional cloning. World J Gastroenterol 2003; 9: 1646-1656 [PMID: 12918095]
2. Hampe J, Hermann B, Bridger S, MacPherson AJ, Mathew CG, Schreiber S. The interferon-gamma gene as a positional and functional candidate gene for inflammatory bowel disease. Int J Colorectal Dis 1998; 13: 260-263 [PMID: 9870173]
3. Hugot JP, Thomas G. Genome-wide scanning in inflammatory bowel diseases. Dig Dis 1998; 16: 364-369 [PMID: 10207223 DOI: 10.1159/00016893]
4. Wild GE, Rioux JD. Genome scans and positional cloning strategy in IBD: successes and limitations. Best Pract Res Clin Gastroenterol 2004; 18: 541-553 [PMID: 15157826 DOI: 10.1016/j.bpcg.2003.12.007]
5. Basta G. Receptor for advanced glycation endproducts and atherosclerosis. From basic mechanisms to clinical implications. Atherosclerosis 2008; 196: 9-21 [PMID: 17826783 DOI: 10.1016/j.atherosclerosis.2007.07.025]
6. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao E, Esposito C, Hegarty H, Hurley W, Claus M. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987-14997 [PMID: 1218222]
7. Rouhiainen A, Kuja-Panula J, Tumova S, Rauvala H. RAGE-mediated cell signaling. Methods Mol Biol 2013; 963: 229-263 [PMID: 23296615 DOI: 10.1007/978-1-62703-208-0_15]
8. Han SH, Kim YH, Mook-Jung I. RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 2011; 31: 91-97 [PMID: 21347704 DOI: 10.1007/s10059-011-0436-x]
9. Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008; 4: 285-293 [PMID: 18332897 DOI: 10.1038/ncpem0786]
10. Foell D, Wittkowski H, Roth J. Mechanisms of disease: a “DAMP” view of inflammatory arthritis. Nat Clin Pract Rheumatol 2007; 3: 382-390 [PMID: 17599072 DOI: 10.1038/ncprheum0531]
11. Martens HA, Niemhuis HL, Gross S, van der Steege G, Bijl M. Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis. Lupus 2012; 21: 959-968 [PMID: 22513366 DOI: 10.1177/1949091611444495]
12. Li K, Zhao B, Dai D, Yao S, Liang W, Yao L, Yang Z. A functional p.82G&gt;Gt;S polymorphism in the RAGE gene is associated with multiple sclerosis in the Chinese population. Mult Scler 2011; 17: 914-921 [PMID: 21511691 DOI: 10.1177/1352458511410352]
13. Dabritz J, Friedrichs F, Weinlage T, Hampe J, Kucharcik T, Lügtering A, Broeckel U, Schreiber S, Trott M, Foell D. The functional -374T/A polymorphism of the receptor for advanced glycation end products may modulate Crohn’s disease. Am J Gastrointest Liver Physiol 2011; 300: G823-G832 [PMID: 21311028 DOI: 10.1152/ajpgi.00115.2010]
14. Lieliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Grüne HJ, Kurschus FC, Schmidt AM, Yan SD, Martin E, Schleicher E, Stern DM, Hämminger G, Nau, Groth PP, Arnold B. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113: 1641-1650 [PMID: 15173891]
15. Malherbe P, Richards JG, Gaillard H, Thompson A, Diener C, Schuler A, Huber G. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res 1999; 71: 159-170 [PMID: 10521570 DOI: 10.1016/S0169-328X(99)00174-6]
16. Schlueter C, Hauke S, Flohr AM, Rogalla P, Bullerdiek J. Tissue-specific expression patterns of the RAGE receptor and its soluble forms—a result of regulated alternative splicing? Biochim Biophys Acta 2005; 1630: 1-6 [PMID: 14580673 DOI: 10.1016/j.bbaexp.2003.08.008]
17. Hudson BI, Carber AM, Harja E, Kalea AZ, Arriero M, Yang H, Grant PJ, Schmidt AM. Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008; 22: 1572-1580 [PMID: 18089847 DOI: 10.1096/fj.07-9900com]
18. Ding Q, Keller JN. Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain. Neurosci Lett 2005; 373: 67-72 [PMID: 15555779 DOI: 10.1016/j.neulet.2004.09.059]
19. Sterenczak KA, Nolle I, Murua Escobar H. RAGE splicing variants in mammals. Methods Mol Biol 2013; 963: 265-276 [PMID: 23296616 DOI: 10.1007/978-1-62703-208-0_16]
20. Khanna M, Park P, Zirvi M, Cao W, Picon A, Day J, Paty P, Barany F. Multiplex PCR/LDR for detection of K-ras mutations in primary colon tumors. Oncogene 1999; 18: 27-38 [PMID: 9926917 DOI: 10.1038/sj.onc.1202291]
21. Stram DO, Leigh Pearce C, Breitsky F, Freedman M, Hirschhorn JN, Altshuler D, Colonol LN, Henderson BE, Thomas DC. Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003; 55: 179-190 [PMID: 14566096 DOI: 10.1159/000073202]
22. Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001; 50: 1505-1511 [PMID: 11375334 DOI: 10.2337/
Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, Bucciarelli LG, Moser B, Moxley G, Itescu S, Grant P, Gregersen PK, Stern DM, Schmidt AM. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. *Genes Immun* 2002; 3: 123-135 [PMID: 12070776 DOI: 10.1038/sj.gene.6363861]

Osawa M, Yamamoto Y, Munesue S, Murakami N, Sakurai S, Watanabe T, Yonekura H, Uchigata Y, Iwamoto Y, Yamamoto H. De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. *Biochim Biophys Acta* 2007; 1770: 1468-1474 [PMID: 17714874]

Jang Y, Kim JY, Kang SM, Kim JS, Chae JS, Kim OY, Koh SJ, Lee HC, Ahn CW, Song YD, Lee JH. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. *Metabolism* 2007; 56: 199-205 [PMID: 17224333 DOI: 10.1016/j.metabol.2006.09.013]

Wang Z, Hu J, Fan R, Zhou J, Zhong J. Association between CD14 gene C-260T polymorphism and inflammatory bowel disease: a meta-analysis. *PLoS One* 2012; 7: e45144 [PMID: 23049772 DOI: 10.1371/journal.pone.0045144]

**P-Reviewers**: Soriano-Ursua M, Zhu X  
**S-Editor**: Gou SX  
**L-Editor**: Ma JY  
**E-Editor**: Wang CH
